CoChat

Multiple sclerosis and depression: influence of interferon b therapy

Zephir, Hélène, De Seze, Jérôme, Stojkovic, Tanya, Delisse, Brigitte, Ferriby, Didier, Cabaret, Marilyn, Vermersch, Patrick · 2003 · Multiple Sclerosis Journal
Cited by 73

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background and objectives: Depression is frequently part of the clinical picture of multiple sclerosis (MS). Major depression affects one in two patients with MS during the course of their lifetime. O ur objectives were to determine first, whether interferon b-1a (IFNb-1a) treatment increases the risk or level of depression and, secondly, whether depression status and depression evolution are related to the clinical characteristics of the disease. Patients and methods: We investigated 106 consecutive patients with relapsing-remitting MS treated with IFNb-1a (Avonex®). Patients with evidence of severe depression were excluded. The depression status, scored on the Beck Depression Inventory (BDI-II) (stratified as minimum, mild, moderate or severe level), and disability, scored on the Expanded Disability Status Scale (EDSS), were evaluated before and after 12 months of IFNb-1a treatment. Results: At baseline, 85% of patients had a minimum or a mild depression status and after 12 months of treatment most of them (83%) retained their baseline status. Beck scores before and after treatment were not significantly different (P =0.63). There was no correlation between age, gender, duration of illness or EDSS score and Beck score at baseline (P =0.696). Patients with disability progression after one year of IFNb-1a treatment had a significantly higher Beck score at baseline than patients without disability progression (P =0.003). Conclusion: IFNb-1a (Avonex®) does not seem to significantly influence the depression status of MS patients even in those with disability progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1191/1352458503ms915oa

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 73

Metadata

Authors
Zephir, H., De Seze, J., Stojkovic, T., Delisse, B., Ferriby, D., Cabaret, M., & Vermersch, P.
Venue
Multiple Sclerosis Journal
Published
2003-06
Volume
9
Issue
3
Pages
284-288
ISSN
  • 1352-4585 (ISSN-L)
  • 1477-0970
OpenAlex
W2162821925
Cited by
73
References
3
FWCI
4.57
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiple sclerosis and depression: influence of interferon b therapy. https://app.cochat.ai/papers/10.1191/1352458503ms915oa
The paper
Zephir, H., De Seze, J., Stojkovic, T., Delisse, B., Ferriby, D., Cabaret, M., & Vermersch, P. (2003). Multiple sclerosis and depression: influence of interferon b therapy. Multiple Sclerosis Journal. https://doi.org/10.1191/1352458503ms915oa

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.